Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer.
Pharmacoecon Open
; 7(3): 455-467, 2023 May.
Article
in En
| MEDLINE
| ID: mdl-36811822
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Health_economic_evaluation
/
Prognostic_studies
Aspects:
Patient_preference
Language:
En
Journal:
Pharmacoecon Open
Year:
2023
Document type:
Article
Affiliation country:
Netherlands
Country of publication:
Switzerland